Drug developer uses RWE to research psychedelic therapies
Written by Jenni Spinner,
The UK-based development and research firm hopes to accelerate patient access to psychedelic therapies for treatment of various mental health conditions. The pharmaceutical treatment options for patients suffering from mental illnesses are broader than ever before. Still, some patients are dealing with treatment-resistant ailments, and other patients are diagnosed with conditions that have few or no treatment options at all. Albert Labs aims to offer hope to patients looking for relief for their mental health struggles. The company is using real-world evidence studies to help patients suffering from a range of mental-health challenges gain access to MDMA, psilocybin, psilocin and other psychedelics. Outsourcing-Pharma recently spoke with Albert Labs chief medical officer Malcolm Barratt-Johnson—a 22-year industry vet who’s worked for AstraZeneca, Roche and other leading organizations—about the company’s work, and the path forward.